Relay Historical Income Statement

RLAY Stock

USD 2.99 0.13 4.55%

Historical analysis of Relay Therapeutics income statement accounts such as Selling General Administrative of 52.8 M, Total Revenue of 14 M, Other Operating Expenses of 250.8 M or Research Development of 201 M can show how well Relay Therapeutics performed in making a profits. Evaluating Relay Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Relay Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Relay Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Relay Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

About Relay Income Statement Analysis

Relay Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Relay Therapeutics shareholders. The income statement also shows Relay investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Relay Therapeutics Income Statement Chart

At this time, Relay Therapeutics' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 36.5 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 4.3 M in 2025.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Relay Therapeutics. It is also known as Relay Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Relay Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Relay Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.At this time, Relay Therapeutics' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 36.5 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 4.3 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Income	8.8M	31.0M	34.7M	36.5M
Net Interest Income	8.8M	31.0M	34.7M	36.5M

Interest Income Net Interest Income

Relay Therapeutics income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Non Operating Income Net Other	Non Recurring	Selling And Marketing Expenses
Net Interest Income		1.0	0.84	0.76	0.81	-0.78	-0.76	-0.88	0.83	-0.88	0.81	0.84	-0.76	1.0	-0.65	-0.85	0.22	0.86	0.91	-0.78	-0.78
Interest Income	1.0		0.84	0.76	0.81	-0.78	-0.76	-0.88	0.83	-0.88	0.81	0.84	-0.76	1.0	-0.65	-0.85	0.22	0.86	0.91	-0.78	-0.78
Depreciation And Amortization	0.84	0.84		0.98	0.98	-0.92	-0.91	-0.94	0.98	-0.94	0.98	1.0	-0.91	0.84	-0.84	-0.57	0.39	0.97	0.78	-0.5	-0.5
Selling General Administrative	0.76	0.76	0.98		0.99	-0.94	-0.93	-0.94	0.98	-0.94	0.99	0.98	-0.93	0.76	-0.88	-0.48	0.35	0.94	0.74	-0.43	-0.43
Other Operating Expenses	0.81	0.81	0.98	0.99		-0.94	-0.92	-0.96	1.0	-0.96	1.0	0.98	-0.92	0.81	-0.85	-0.52	0.27	0.96	0.8	-0.44	-0.44
Operating Income	-0.78	-0.78	-0.92	-0.94	-0.94		1.0	0.97	-0.94	0.97	-0.94	-0.92	1.0	-0.78	0.97	0.49	-0.1	-0.89	-0.72	0.54	0.54
Net Income From Continuing Ops	-0.76	-0.76	-0.91	-0.93	-0.92	1.0		0.96	-0.91	0.96	-0.92	-0.91	1.0	-0.76	0.98	0.48	-0.09	-0.87	-0.7	0.55	0.55
Ebit	-0.88	-0.88	-0.94	-0.94	-0.96	0.97	0.96		-0.97	1.0	-0.96	-0.94	0.96	-0.88	0.88	0.64	-0.13	-0.93	-0.87	0.61	0.61
Research Development	0.83	0.83	0.98	0.98	1.0	-0.94	-0.91	-0.97		-0.97	1.0	0.98	-0.91	0.83	-0.84	-0.54	0.25	0.97	0.82	-0.44	-0.44
Ebitda	-0.88	-0.88	-0.94	-0.94	-0.96	0.97	0.96	1.0	-0.97		-0.96	-0.94	0.96	-0.88	0.88	0.64	-0.13	-0.93	-0.87	0.61	0.61
Total Operating Expenses	0.81	0.81	0.98	0.99	1.0	-0.94	-0.92	-0.96	1.0	-0.96		0.98	-0.92	0.81	-0.85	-0.52	0.27	0.96	0.8	-0.44	-0.44
Reconciled Depreciation	0.84	0.84	1.0	0.98	0.98	-0.92	-0.91	-0.94	0.98	-0.94	0.98		-0.91	0.84	-0.84	-0.57	0.39	0.97	0.78	-0.5	-0.5
Income Before Tax	-0.76	-0.76	-0.91	-0.93	-0.92	1.0	1.0	0.96	-0.91	0.96	-0.92	-0.91		-0.76	0.98	0.48	-0.09	-0.87	-0.7	0.55	0.55
Total Other Income Expense Net	1.0	1.0	0.84	0.76	0.81	-0.78	-0.76	-0.88	0.83	-0.88	0.81	0.84	-0.76		-0.65	-0.85	0.22	0.86	0.91	-0.78	-0.78
Net Income	-0.65	-0.65	-0.84	-0.88	-0.85	0.97	0.98	0.88	-0.84	0.88	-0.85	-0.84	0.98	-0.65		0.35	-0.07	-0.8	-0.54	0.49	0.49
Income Tax Expense	-0.85	-0.85	-0.57	-0.48	-0.52	0.49	0.48	0.64	-0.54	0.64	-0.52	-0.57	0.48	-0.85	0.35		-0.14	-0.65	-0.84	0.89	0.89
Gross Profit	0.22	0.22	0.39	0.35	0.27	-0.1	-0.09	-0.13	0.25	-0.13	0.27	0.39	-0.09	0.22	-0.07	-0.14		0.3	0.15	-0.12	-0.12
Cost Of Revenue	0.86	0.86	0.97	0.94	0.96	-0.89	-0.87	-0.93	0.97	-0.93	0.96	0.97	-0.87	0.86	-0.8	-0.65	0.3		0.81	-0.52	-0.52
Non Operating Income Net Other	0.91	0.91	0.78	0.74	0.8	-0.72	-0.7	-0.87	0.82	-0.87	0.8	0.78	-0.7	0.91	-0.54	-0.84	0.15	0.81		-0.7	-0.7
Non Recurring	-0.78	-0.78	-0.5	-0.43	-0.44	0.54	0.55	0.61	-0.44	0.61	-0.44	-0.5	0.55	-0.78	0.49	0.89	-0.12	-0.52	-0.7		1.0
Selling And Marketing Expenses	-0.78	-0.78	-0.5	-0.43	-0.44	0.54	0.55	0.61	-0.44	0.61	-0.44	-0.5	0.55	-0.78	0.49	0.89	-0.12	-0.52	-0.7	1.0

Click cells to compare fundamentals

Relay Therapeutics Account Relationship Matchups

Relay Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Net Interest Income	3.4M	830K	8.8M	31.0M	34.7M	36.5M
Interest Income	3.4M	830K	8.8M	31.0M	34.7M	36.5M
Depreciation And Amortization	3.5M	3.9M	4.1M	5.3M	5.5M	4.3M
Selling General Administrative	38.6M	57.4M	66.0M	75.0M	76.6M	52.8M
Total Revenue	82.7M	3.0M	1.4M	25.5M	10.0M	14.0M
Other Operating Expenses	138.5M	230.0M	312.3M	398.5M	382.5M	250.8M
Operating Income	(55.8M)	(364.7M)	(299.3M)	(373M)	(372.5M)	(353.8M)
Net Income From Continuing Ops	(52.4M)	(363.9M)	(290.5M)	(342.0M)	(337.7M)	(354.6M)
Ebit	(55.8M)	(226.1M)	(311.0M)	(379.4M)	(385.7M)	(366.4M)
Research Development	99.9M	172.7M	246.4M	330.0M	319.1M	201.0M
Ebitda	(52.2M)	(222.2M)	(306.8M)	(374.2M)	(380.2M)	(361.2M)
Total Operating Expenses	138.5M	230.0M	312.3M	398.5M	382.5M	250.8M
Reconciled Depreciation	3.5M	3.9M	4.1M	5.3M	5.5M	4.3M
Income Before Tax	(52.4M)	(363.9M)	(290.5M)	(342.0M)	(337.7M)	(354.6M)
Total Other Income Expense Net	3.4M	826K	8.8M	31.0M	34.8M	36.5M
Net Income Applicable To Common Shares	(75.3M)	(230.2M)	(363.9M)	(290.5M)	(261.5M)	(274.5M)
Net Income	(49.0M)	(496.8M)	(254.3M)	(342.0M)	(337.7M)	(354.6M)
Income Tax Expense	(3.4M)	132.9M	(36.3M)	(37.5M)	(337.7M)	(320.8M)
Gross Profit	79.1M	(896K)	(2.7M)	20.3M	10.0M	13.7M
Cost Of Revenue	3.5M	3.9M	4.1M	5.3M	6.1M	4.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Relay Historical Income Statement

About Relay Income Statement Analysis

Relay Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Relay Therapeutics income statement Correlations

Relay Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Relay Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Relay Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Income	+ 1.0	Net Interest Income
Total Other Income Expense Net	+ 1.0	Net Interest Income
Total Other Income Expense Net	+ 1.0	Interest Income
Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses

Ebitda	- 0.97	Research Development
Research Development	- 0.97	Ebit
Total Operating Expenses	- 0.96	Ebitda
Total Operating Expenses	- 0.96	Ebit
Ebitda	- 0.96	Other Operating Expenses
Ebit	- 0.96	Other Operating Expenses